GX-1 ( Ariflex )
Next-Generation Humanized CAR Therapy
GX-01, also known as Ariflex, is the lead clinical candidate developed by Cambridge GenetiX and is currently progressing through the regulatory approval pathway.
Ariflex is a fully humanized anti-scFv fragment integrated with a second-generation Chimeric Antigen Receptor (CAR) platform. This advanced design enables high target specificity, enhanced therapeutic potency, and superior safety profiles compared to conventional CAR-based therapies.
- Lead clinical-stage therapeutic candidate
- Fully humanized anti-scFv fragment
- Second-generation CAR technology
- Designed for scalable and automated manufacturing
GX-01 also known as Ariflex is our lead clinical Candidate which is undergoing a regulatory approval process. GX-01 is fully Humanized anti ScFV Fragment with 2nd Generation of Chimeric Antigen receptor providing unmatchable safety and efficacy in patients.
A Lead Clinical-Stage, Fully Humanized CAR-Based Cell & Gene Therapy
Lead Clinical Candidate
GX-01 (Ariflex) is Cambridge GenetiX’s primary clinical-stage therapy, currently progressing through regulatory evaluation, reflecting its strong safety, efficacy, and development readiness.
Enhanced Safety and Reduced Immunogenicity
Ariflex utilizes a fully humanized anti-scFv fragment, minimizing immune reactions while improving patient tolerability and long-term therapeutic performance.
Second-Generation CAR Technology
Built on advanced second-generation Chimeric Antigen Receptor architecture, GX-01 delivers high target specificity, sustained activity, and superior clinical efficacy.
Automated & Scalable Platform
Developed using Cambridge GenetiX’s novel and automated cell and gene therapy platform, Ariflex ensures reproducible quality, scalability, and reliable treatment outcomes.